Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The updated benzodiazepine boxed warning: What you need to know

Christy Huff, MD
Meds
March 23, 2021
1K Shares
Share
Tweet
Share

“I am [sharing] my story as I would like to raise awareness about the dangers of benzodiazepines and advocate for stronger warning labels.”

I paused to wipe away tears before typing the final words of Bobbi’s report into the FDA’s MedWatch online reporting system. Bobbi, a physician assistant, was forced into medical detox by her state medical board after suffering adverse effects from prescription clonazepam. Six years later, she was still too cognitively impaired to report her harm without assistance, so she asked for my help to spare others the same fate.

“I took the medication only as prescribed,” Bobbi said. After her benzodiazepine was stopped abruptly, she suffered multiple disabling neurological symptoms, including seizures, cognitive and visual impairment, difficulty walking, and hand contractures, leaving her unable to work. Bobbi is one of many patients my advocacy organization helped report their harm to the FDA. Our goal was to raise awareness of the adverse effects of benzodiazepines and advocate for stronger warning labels.

Thus, I was pleasantly surprised last September to see the FDA’s drug safety communication announcing an update to the boxed warning for benzodiazepines “to address the serious risks of abuse, addiction, physical dependence, and withdrawal reactions.” Curious, I filed a FOIA request for the FDA’s 175-page report on benzodiazepines. Many of the document’s conclusions raise the same concerns benzodiazepine safety advocates have had for decades.

First, while benzodiazepine abuse and addiction are a problem, they primarily occur in the context of polysubstance use. The issue of addiction receives a lot of attention, so I will focus on the more under-recognized yet equally devastating problems of physical dependence and withdrawal. The FDA concluded this is a significant problem as well, mainly based on their review of 104 cases from the roughly 300,000 benzodiazepine adverse event reports in the FAERS database. Some of the important findings from the case series are:

  • Adverse events can occur with prescribed therapeutic use: This was true for all but 2 cases in the series.
  • Withdrawal can be a long process: The median length of withdrawal symptoms was 9.5 months, with the longest case in the series lasting 8 years!
  • Physical dependence can occur within days or weeks: Median time to onset was 14 days (ranging from 1 day to 4 years).
  • Abrupt and over-rapid tapers are harming patients: This was a major theme in the 6 example narratives provided. The FDA reviewers postulated that these harms were potentially preventable with a slow taper.
  • Physician education about benzodiazepine safety is lacking: The FDA found that there is a “lack of awareness or misconceptions among prescribers about appropriate management of patients taking benzodiazepines.” Fourteen reports requested better prescriber education about the potential for dependence and withdrawal, along with stronger warning labels. Misdiagnosis of benzodiazepine withdrawal was a common theme, often resulting in prescribers increasing the dose of benzodiazepine. Patients were told erroneously that they could safely stop because they were taking a “low dose,” or were instructed to “taper” by halving their dose.

Based on these findings, the FDA recommended an updated boxed warning and standardization of product labels across the drug class. They recommended judicious prescribing and a gradual taper to mitigate withdrawal reactions. While I am optimistic about these changes, the updated warning doesn’t tell the whole story. After reviewing the newly updated Xanax Medication Guide, I have some concerns:

  • There is little guidance as to what constitutes a gradual taper. The warning advises: “No standard benzodiazepine tapering schedule is suitable for all patients; therefore, create a patient-specific plan to gradually decrease the dosage.” Beyond recommending a slower taper rate if withdrawal symptoms develop, what little advice there is regarding a gradual taper may be harmful. The maximum recommended dosage reduction of Xanax—0.5 mg (the equivalent of 10 mg Valium!) every 3 days—is ridiculously fast and a sure-fire way to send patients to the ER with withdrawal symptoms. Feedback from the online benzodiazepine community reveals a more conservative approach— <5 percent to 10 percent dosage reductions from the current dose monthly—is better tolerated.
  • Protracted withdrawal is not rare, and it can be disabling. The Medication Guide states that “in some cases,” a protracted withdrawal syndrome can develop, and it can last over 12 months. While I was happy to see this acknowledged, there is no inkling of the level of suffering many patients experience, and that patients like Bobbi remain disabled even years post-cessation. Ashton estimates that 10 percent to 15 percent of patients withdrawing from long-term benzodiazepines will develop chronic symptoms.
  • Slow tapers don’t always mitigate harm. A slow taper can reduce harm, but it’s not bulletproof for preventing severe and protracted withdrawal. I was extremely ill for my entire 3.25-year benzodiazepine taper. At 2 years off, while improved, I still experience life-limiting symptoms. Countless others I’ve met share similar experiences.

Given the FDA’s findings, coupled with my observations from advocacy work, I hope prescribers will read past the risks of abuse and addiction in the updated boxed warning and recognize the serious morbidity that accompanies benzodiazepine physical dependence and withdrawal. Most affected patients are simply taking benzodiazepines as prescribed. The FDA’s recommendations regarding judicious prescribing and a gradual taper should be implemented immediately. I also recommend that patients receive verbal and written informed consent before receiving a prescription, given the serious risks and harms of benzodiazepines.

I agree that a slow taper guided by withdrawal symptoms is the best approach for discontinuation in physically dependent patients. Better provider education about prescribing and deprescribing practices is certainly warranted as well. If Bobbi’s providers had followed the FDA’s current advice for a gradual taper, there’s a good chance she would not be disabled today. Continued reporting of serious outcomes (such as severe and protracted withdrawal and suicides) to the MedWatch program is also critical. Providers need to pick up the slack: Only 18 of the 104 reports in the FAERS case series were filed by health care professionals. Finally, research into the cause and treatment of protracted withdrawal syndrome is desperately needed.

Christy Huff is a cardiologist and co-director, Benzodiazepine Information Coalition. She can be reached on Twitter @christyhuffMD.

Image credit: Shutterstock.com

Prev

Not throwing away my shot: Health care workers show confidence in the COVID-19 vaccine

March 23, 2021 Kevin 0
…
Next

Solving imposter syndrome in physicians [PODCAST]

March 23, 2021 Kevin 0
…

Tagged as: Psychiatry

Post navigation

< Previous Post
Not throwing away my shot: Health care workers show confidence in the COVID-19 vaccine
Next Post >
Solving imposter syndrome in physicians [PODCAST]

More by Christy Huff, MD

  • Stop cutting patients off their prescribed benzodiazepines

    Christy Huff, MD
  • A Xanax prescription that should have been rejected

    Christy Huff, MD
  • Don’t miss this adverse drug reaction when tapering benzodiazepines

    Christy Huff, MD

Related Posts

  • 10 tips to help patients through benzodiazepine withdrawal

    Christy Huff, MD
  • Black boxes: health warning or profit warning?

    Martha Rosenberg
  • The tip of the iatrogenic benzodiazepine iceberg

    Nicole Lamberson, PA
  • My Klonopin withdrawal story

    Bethany Silverman
  • The life cycle of medication consumption

    Fery Pashang, PharmD
  • The abundant and colorful world of pharmaceuticals

    Fery Pashang, PharmD

More in Meds

  • Levamisole is good for your dog, but bad for your cocaine

    Robert Killeen, MD
  • 13.1 million missing Americans since 1980. Where’s the outrage?

    Steve Burgess, MD
  • Ketamine for mental health conditions: What every primary care physician needs to know

    Carlene MacMillan, MD & L. Alison McInnes, MD
  • Learn to be a Narcan hero: a comic tutorial

    Emily Watters, MD
  • The preference for insurance coverage of opioids over non-pharmaceutical options explained

    Amy Baxter, MD
  • A comic reveals the terrifying truth about fentanyl

    Emily Watters, MD
  • Most Popular

  • Past Week

    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • Inside the grueling life of a surgery intern

      Randall S. Fong, MD | Physician
    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • COVID-19 unleashed an ongoing crisis of delirium in hospitals

      Christina Reppas-Rindlisbacher, MD, Nathan Stall, MD, and Paula Rochon, MD | Conditions
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
  • Recent Posts

    • How to facilitate caregiver learning and support to improve clinical care outcomes

      Kerri Milyko, PhD | Tech
    • Air quality alert: Reducing our carbon footprint in health care

      Shreya Aggarwal, MD | Conditions
    • Exploring HIV care and advocacy [PODCAST]

      The Podcast by KevinMD | Podcast
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • The art of pediatrics: Connecting through observation

      Alexander Rakowsky, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Are Obesity Drugs for Adolescents Cost-Effective?
  • Lab Tests That Escape FDA Oversight May Come Under Agency Review
  • Fezolinetant Benefits Women Not Suited for Hormone Therapy
  • Low Tidal Volume Compliance Still Lacking in Mechanical Ventilation
  • IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for Myeloma

Meeting Coverage

  • Fezolinetant Benefits Women Not Suited for Hormone Therapy
  • Plant-Based Estrogen Improves Lipids in Postmenopausal Women
  • New Schizophrenia Treatments Are Coming: Don't Panic
  • Loneliness Needs to Be Treated Like Any Other Health Condition, Researcher Suggests
  • Stopping Medical Misinformation Requires Early Detection
  • Most Popular

  • Past Week

    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Reigniting after burnout: 3 physician stories

      Kim Downey, PT | Physician
    • Inside the grueling life of a surgery intern

      Randall S. Fong, MD | Physician
    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • COVID-19 unleashed an ongoing crisis of delirium in hospitals

      Christina Reppas-Rindlisbacher, MD, Nathan Stall, MD, and Paula Rochon, MD | Conditions
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
  • Past 6 Months

    • Medical gaslighting: a growing challenge in today’s medical landscape

      Tami Burdick | Conditions
    • I want to be a doctor who can provide care for women: What states must I rule out for my medical education?

      Nandini Erodula | Education
    • Balancing opioid medication in chronic pain

      L. Joseph Parker, MD | Conditions
    • The erosion of patient care

      Laura de la Torre, MD | Physician
    • Mourning the silent epidemic: the physician suicide crisis and suggestions for change

      Amna Shabbir, MD | Physician
    • I’m a doctor, and I almost died during childbirth

      Bayo Curry-Winchell, MD | Physician
  • Recent Posts

    • How to facilitate caregiver learning and support to improve clinical care outcomes

      Kerri Milyko, PhD | Tech
    • Air quality alert: Reducing our carbon footprint in health care

      Shreya Aggarwal, MD | Conditions
    • Exploring HIV care and advocacy [PODCAST]

      The Podcast by KevinMD | Podcast
    • A teenager’s perspective: the pressing need for mental health days in schools

      Ruhi Saldanha | Conditions
    • Challenging the diagnosis: dehydration or bias?

      Sydney Lou Bonnick, MD | Physician
    • The art of pediatrics: Connecting through observation

      Alexander Rakowsky, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

The updated benzodiazepine boxed warning: What you need to know
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...